Insulin Regimens of the Study Subjects

Insulin regimens of the study subjects

Type of insulin therapy*
Diabetes duration / Type 1 n (%) patients / Type 2 n (%) patients / Type 3 n (%) patients / Type 4 n (%) patients / Type 5 n (%) patients / Type 6 n (%) patients
At onset of diabetes / 150
(86.7%) / 13
(7.5%) / 2
(1.2%) / 0 / 7
(4%) / 1
(0.6%)
First 6 months / 129 (74.6%) / 23 (13.3%) / 1 (0.6 %) / 0 / 6 (3.5%) / 14 (8.0%)
First year / 100 (57.8%) / 27 (15.6%) / 2 (1.2%) / 1 (0.6 %) / 8 (4.6%) / 35 (20.2%)
Second year / 62 (44.3%) / 22 (15.7%) / 3 (2.1%) / 3 (2.1%) / 1 (0.8 %) / 49 (35%)
Third year / 41 (35.3%) / 18 (15.5%) / 1 (0.9 %) / 5 (4.3%) / 1 (0.9 %) / 50 (43.1%)
Fourth year / 28 (29.8%) / 15 (16%) / 1 (1.1%) / 6 (6.4%) / 2 (2.1%) / 42 (44.7%)
Fifth year / 20 (28.2%) / 7 (9.9%) / 1 (1.4%) / 6 (8.5%) / 1 (1.4%) / 36 (50.6%)
Sixth year / 16 (27.6%) / 5 (8.6%) / 3 (5.2%) / 7 (12.1%) / 0 / 27 (46.5%)
Seventh year / 15 (30.6%) / 3 (6.2%) / 1 (2%) / 5 (10.2%) / 0 / 25 (51%)
Eight year / 9 (31%) / 4 (13.8%) / 0 / 2 (6.9%) / 0 / 14 (48.3%)
Last visit / 45 (26%) / 14 (8.1%) / 10 (5.8%) / 17 (9.8%) / 2 (1.1%) / 85 (49.2%)

*Type 1: 1-3 injections/day of neutral protamine Hagedorn (NPH) + 2-3 injections/day of human regular insulin; Type 2: 2-3 injections/day of NPH + 2-3 injections/day of rapid- acting insulin analogues (Lispro/Aspart); Type 3: 1 injection/day of long-acting analogue (glargine/Detemir) + 2-3 injections/day of human regular insulin; Type 4: 1-2 injections/day of long-acting analogue +3 injections/day of rapid- acting insulin analogues; Type 5: 3 injections/day of NPH only; Type 6: basal-bolus with continuous subcutaneous insulin infusion (CSII).